Free from exaggerated anti-aging or medical claims
My wife Monica and I have documented thousands of experiments on ourselves, figuring out what actually moves the needle versus whats just hype
The mechanistic hypothesis: Semaglutide activates GLP-1R, appetite suppression, glycemic control Cagrilintide activates amylin receptors, appetite suppression via the area postrema, slowing of gastric evacuation Two independent mechanisms of appetite suppression a supra-additive effect In Phase 1b and Phase 2 trials the combination showed a stronger effect than either component alone : Semaglutide alone: 14.9 % (STEP-1) Cagrilintide alone (Phase 2): 10.8 % CagriSema combination (Phase 2): 15.6 % CagriSema Phase 3 (REDEFINE 1): 25.3 % CagriSema thus becomes the largest body-weight signal reported in the published incretin literature to date , stronger than Tirzepatide (22.5 % in SURMOUNT-1) and comparable to Retatrutide
We mean this sincerely: researchers pursuing BPC-157 gastroparesis studies are working on a genuinely novel therapeutic angle, but the leap from 'works in rats' to 'safe and effective in humans' requires Phase I safety trials, Phase II dose-finding studies, and Phase III controlled efficacy comparisons against existing treatments like metoclopramide or domperidone
GHK-Cu plus TB-500: A recovery-focused pairing, with both studied for angiogenesis and wound healing
